Zobrazeno 1 - 10
of 33
pro vyhledávání: '"David E Piccioni"'
Autor:
David E Piccioni, Achal Singh Achrol, Lesli A Kiedrowski, Kimberly C Banks, Najee Boucher, Garni Barkhoudarian, Daniel F Kelly, Tiffany Juarez, Richard B Lanman, Victoria M Raymond, Minhdan Nguyen, Judy D Truong, Annie Heng, Jaya Gill, Marlon Saria, Sandeep C Pingle, Santosh Kesari
Publikováno v:
CNS Oncology, Vol 8, Iss 2 (2019)
Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested cl
Externí odkaz:
https://doaj.org/article/ef6262da7ada4d6092de61d74bc2de20
Autor:
Paul Manning, Shanmukha Srinivas, Divya S. Bolar, Matthew K. Rajaratnam, David E. Piccioni, Carrie R. McDonald, Jona A. Hattangadi-Gluth, Nikdokht Farid
Publikováno v:
Frontiers in Radiology, Vol 4 (2024)
PurposeConventional contrast-enhanced MRI is currently the primary imaging technique used to evaluate radiation treatment response in meningiomas. However, newer perfusion-weighted MRI techniques, such as 3D pseudocontinuous arterial spin labeling (3
Externí odkaz:
https://doaj.org/article/ec81c74f845f477685e71f7848c5c912
Publikováno v:
Interdisciplinary Neurosurgery, Vol 28, Iss , Pp 101526- (2022)
Background and Importance:: Staged surgery has been used to treat large skull base tumors but is rarely used for intrinsic brain tumors, despite the fact that extent of resection (EOR) is associated with improved survival. A number of questions remai
Externí odkaz:
https://doaj.org/article/07bdb83d9c734e72a6555f60fde5d192
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Background Neurologic toxicities with immune therapy are rare, but can cause devastating and often permanent injury when they occur. Although there is increasing interest in the potential synergism between immune therapy and radiation, it is
Externí odkaz:
https://doaj.org/article/96391bc275fa40fca82d3b58c60e9ecd
Autor:
Priscilla K. Brastianos, Erin L. Twohy, Elizabeth R. Gerstner, Timothy J. Kaufmann, A. John Iafrate, Jochen Lennerz, Suriya Jeyapalan, David E. Piccioni, Varun Monga, Camilo E. Fadul, David Schiff, Jennie W. Taylor, Sajeel A. Chowdhary, Chetan Bettegowda, George Ansstas, Macarena De La Fuente, Mark D. Anderson, Nicole Shonka, Denise Damek, Jose Carrillo, Lara J. Kunschner-Ronan, Rekha Chaudhary, Kurt A. Jaeckle, Francis M. Senecal, Thomas Kaley, Tara Morrison, Alissa A. Thomas, Mary R. Welch, Fabio Iwamoto, David Cachia, Adam L. Cohen, Shivangi Vora, Michael Knopp, Ian F. Dunn, Priya Kumthekar, Jann Sarkaria, Susan Geyer, Xiomara W. Carrero, Maria Martinez-Lage, Daniel P. Cahill, Paul D. Brown, Caterina Giannini, Sandro Santagata, Frederick G. Barker, Evanthia Galanis
Publikováno v:
Journal of Clinical Oncology. 41:618-628
PURPOSE Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with NF2 loss. Given the predominance of NF2 mutations in meningiomas, we eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13d92dd4797c6a215de625e0d33d141d
https://doi.org/10.1200/jco.21.02371
https://doi.org/10.1200/jco.21.02371
Autor:
Razelle Kurzrock, Barbara A. Parker, Kelly A. Shimabukuro, Richard B. Schwab, Paul T. Fanta, David E. Piccioni, Gregory A. Daniels, Maria Schwaederle
Despite the increased use of molecular diagnostics, the extent to which patients who have these tests harbor potentially actionable aberrations is unclear. We retrospectively reviewed 439 patients with diverse cancers, for whom next-generation sequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::058e4b1109886d1a1ecbcc1c7fec407b
https://doi.org/10.1158/1535-7163.c.6536761.v1
https://doi.org/10.1158/1535-7163.c.6536761.v1
Autor:
Razelle Kurzrock, Scott M. Lippman, Paul T. Fanta, Julio Romero, Lyudmila A. Bazhenova, Teresa L. Helsten, Santosh Kesari, David E. Piccioni, Gregory A. Daniels, Richard B. Schwab, Barbara A. Parker, Maria Schwaederle
By profiling their patients' tumors, oncologists now have the option to use molecular results to match patients with drug(s) based on specific biomarkers. In this observational study, 347 patients with solid advanced cancers and next-generation seque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d38652e4f16dcdeda5f7bb5f11ff928f
https://doi.org/10.1158/1535-7163.c.6538405.v1
https://doi.org/10.1158/1535-7163.c.6538405.v1
Autor:
Razelle Kurzrock, Scott M. Lippman, Paul T. Fanta, Julio Romero, Lyudmila A. Bazhenova, Teresa L. Helsten, Santosh Kesari, David E. Piccioni, Gregory A. Daniels, Richard B. Schwab, Barbara A. Parker, Maria Schwaederle
Supplemental Methods 1) Sequencing: (182 and 236 gene lists) 2)Therapy 3) Matching Score 4) Statistical Analysis (patient's characteristics, study endpoints and definitions, analyses performed);Supplemental Table 1. Patient characteristics; Supplemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72e4f8a450bacecb9c256df081ef4ca4
https://doi.org/10.1158/1535-7163.22506457
https://doi.org/10.1158/1535-7163.22506457
Autor:
Razelle Kurzrock, Barbara A. Parker, Megumi Ikeda, Olivier Harismendy, Sandip P. Patel, Richard B. Schwab, Santosh Kesari, David E. Piccioni, Paul T. Fanta, Hatim Husain, Maria Schwaederle
Purpose: There is a growing interest in using circulating tumor DNA (ctDNA) testing in patients with cancer.Experimental Design: A total of 168 patients with diverse cancers were analyzed. Patients had digital next-generation sequencing (54 cancer-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06d2c0bd1df340397479395e76273575
https://doi.org/10.1158/1078-0432.c.6525516.v1
https://doi.org/10.1158/1078-0432.c.6525516.v1
Autor:
Razelle Kurzrock, Barbara A. Parker, Juliann Chmielecki, Michael E. Goldberg, Paul T. Fanta, David E. Piccioni, Sherri Z. Millis, Cheyennedra C. Bieg-Bourne
Supplemental Table S2 displays the Foundation Medicine 315 gene panel for solid tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b84ef1a4fed778121016a12cb2c3bb
https://doi.org/10.1158/0008-5472.22415378.v1
https://doi.org/10.1158/0008-5472.22415378.v1